IP Library › Granted Patent US 12,285,429
Granted Patent B2
US 12,285,429 · App. 17/922,804 · Granted Apr 29, 2025

CDK inhibitors

Inventors: Zhilong Hu (Shanghai, CN); Hu He (Shanghai, CN); Fei Zhang (Shanghai, CN); Wenge Zhong (Thousand Oaks, CA); Xiaotian Zhu (Newton, MA)
Assignee: Genentech, Inc.
A61K31/506A61K31/5377A61K31/55A61K45/06A61P35/00C07D401/14C07D405/14C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,285,429
App. No.
17/922,804
Filed
Nov 2, 2022
Granted
Apr 29, 2025
Kind
B2
Art Unit
1628
USPC
514/275
Abstract

The invention provides a compound represented by the either of the following structural formulas, or a pharmaceutically acceptable salt, or a stereoisomer thereof, useful for treating cancer.

Claims (14)

1. A compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising an effective amount of the compound of claim 1 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

3. A compound represented by the following structural formula:

or a pharmaceutically acceptable salt thereof.

4. The compound of claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof has an optical purity of 70% or more.

5. The compound of claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof has an optical purity of 90% or more.

6. The compound of claim 1 , wherein the compound or a pharmaceutically acceptable salt thereof has an optical purity of 99% or more.

7. A pharmaceutical composition comprising an effective amount of the compound of claim 6 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

8. The compound of claim 3 , wherein the compound or a pharmaceutically acceptable salt thereof has an optical purity of 70% or more.

9. The compound of claim 3 , wherein the compound or a pharmaceutically acceptable salt thereof has an optical purity of 90% or more.

10. The compound of claim 3 , wherein the compound or a pharmaceutically acceptable salt thereof has an optical purity of 99% or more.

11. A pharmaceutical composition comprising an effective amount of the compound of claim 3 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

12. A pharmaceutical composition comprising an effective amount of the compound of claim 10 or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 18, 2024
From: REGOR PHARMACEUTICALS, INC.; QILU REGOR THERAPEUTICS INC.
To: GENENTECH, INC.
Reel/Frame 069628/0761 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 24, 2023
From: QILU REGOR THERAPEUTICS INC.
To: REGOR PHARMACEUTICALS, INC.
Reel/Frame 065322/0727 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 1, 2022
From: HU, ZHILONG; HE, HU; ZHANG, FEI; ZHONG, WENGE; ZHU, XIAOTIAN
To: QILU REGOR THERAPEUTICS INC.
Reel/Frame 061942/0221 →
Priority Claims (1)
WO PCT/CN2020/088585 · May 5, 2020 · international
Continuity (1)
Related Publication 20230174512A1 · Jun 8, 2023
References Cited (116)
US 6194410B1 · Bos et al. · 2001 [cited by applicant]
US 7855211B2 · Coates et al. · 2010 [cited by applicant]
US 7977477B2 · Berdini et al. · 2011 [cited by applicant]
US 8791136B2 · Goff et al. · 2014 [cited by applicant]
US 8809370B2 · Goff et al. · 2014 [cited by applicant]
US 8980921B2 · Goff et al. · 2015 [cited by applicant]
US 8987303B2 · Goff et al. · 2015 [cited by applicant]
US 9266856B2 · Goff et al. · 2016 [cited by applicant]
US 9663496B2 · Irving et al. · 2017 [cited by applicant]
US 9969719B2 · Ding et al. · 2018 [cited by applicant]
US 10370371B2 · Du et al. · 2019 [cited by applicant]
US 10377742B2 · Goff et al. · 2019 [cited by applicant]
US 10464927B2 · Zheng et al. · 2019 [cited by applicant]
US 10941134B2 · Goff et al. · 2021 [cited by applicant]
US 11352351B2 · Jin et al. · 2022 [cited by applicant]
US 11427548B2 · Crew et al. · 2022 [cited by applicant]
US 20040248903A1 · Gudmundsson et al. · 2004 [cited by applicant]
US 20050049260A1 · Boyd et al. · 2005 [cited by applicant]
US 20090221597A1 · Ruah et al. · 2009 [cited by applicant]
US 20190071427A1 · Zheng et al. · 2019 [cited by applicant]
US 20220296595A1 · Hu et al. · 2022 [cited by applicant]
US 20230174512A1 · Hu et al. · 2023 [cited by applicant]
US 20240033264A1 · Hu et al. · 2024 [cited by applicant]
US 20240066031A1 · Hu et al. · 2024 [cited by applicant]
CA 2956628A1 · 2016 [cited by applicant]
CN 104761544B · 2015 [cited by applicant]
CN 105732615A · 2016 [cited by applicant]
CN 107286134A · 2017 [cited by applicant]
CN 105732615B · 2018 [cited by applicant]
CN 108484606A · 2018 [cited by applicant]
CN 109503573A · 2019 [cited by applicant]
CN 109952295A · 2019 [cited by applicant]
CN 109963842A · 2019 [cited by applicant]
CN 110156754A · 2019 [cited by applicant]
CN 109963842B · 2020 [cited by applicant]
CN 112225724A · 2021 [cited by applicant]
CN 112250669A · 2021 [cited by applicant]
CN 109952295B · 2021 [cited by applicant]
CN 112250669B · 2022 [cited by applicant]
CN 112225724B · 2022 [cited by applicant]
EP 3269715A1 · 2018 [cited by applicant]
EP 3444246A1 · 2019 [cited by applicant]
EP 3620456A1 · 2020 [cited by applicant]
EP 3269715B1 · 2020 [cited by applicant]
JP 2009542604A · 2009 [cited by applicant]
KR 1020180005160 · 2018 [cited by applicant]
WO 199719065A1 · 1997 [cited by applicant]
WO 2003015776A1 · 2003 [cited by applicant]
WO 2003032997A1 · 2003 [cited by applicant]
WO 2003057165A2 · 2003 [cited by applicant]
WO 2005099711A1 · 2005 [cited by applicant]
WO 2006075152A1 · 2006 [cited by applicant]
WO 2007149427A1 · 2007 [cited by applicant]
WO 2008003766A2 · 2008 [cited by applicant]
WO 2009085185A1 · 2008 [cited by applicant]
WO 2009103032A1 · 2009 [cited by applicant]
WO 2010020675A1 · 2010 [cited by applicant]
WO 2010049731A1 · 2010 [cited by applicant]
WO 2010075074A1 · 2010 [cited by applicant]
WO 2010129053A2 · 2010 [cited by applicant]
WO 2011022440A2 · 2011 [cited by applicant]
WO 2011101409A1 · 2011 [cited by applicant]
WO 2011130232A1 · 2011 [cited by applicant]
WO 201216217A1 · 2012 [cited by applicant]
WO 2013014448A1 · 2013 [cited by applicant]
WO 2013173506A2 · 2013 [cited by applicant]
WO 2014144740A1 · 2014 [cited by applicant]
WO 2014181287A1 · 2014 [cited by applicant]
WO 2015030847A1 · 2015 [cited by applicant]
WO 2015058163A2 · 2015 [cited by applicant]
WO 201530847A1 · 2015 [cited by applicant]
WO 2015154039A2 · 2015 [cited by applicant]
WO 2015161285A1 · 2015 [cited by applicant]
WO 2015161287A1 · 2015 [cited by applicant]
WO 2015161288A1 · 2015 [cited by applicant]
WO 201614881A1 · 2016 [cited by applicant]
WO 2016014904A1 · 2016 [cited by applicant]
WO 2016141881A1 · 2016 [cited by applicant]
WO 201615605A1 · 2016 [cited by applicant]
WO 2016015605A1 · 2016 [cited by applicant]
WO 201717783A1 · 2017 [cited by applicant]
WO 2017177836A1 · 2017 [cited by applicant]
WO 2017133701A1 · 2017 [cited by applicant]
WO 2017181177A1 · 2017 [cited by applicant]
WO 2018019204A1 · 2018 [cited by applicant]
WO 2018045956A1 · 2018 [cited by applicant]
WO 2018045957A1 · 2018 [cited by applicant]
WO 2018113771A1 · 2018 [cited by applicant]
WO 2018121766A1 · 2018 [cited by applicant]
WO 2019023553A1 · 2019 [cited by applicant]
WO 2019029663A1 · 2019 [cited by applicant]
WO 2019133864A1 · 2019 [cited by applicant]
WO 2019148161A1 · 2019 [cited by applicant]
WO 2020125513A1 · 2020 [cited by applicant]
WO 2020119739A1 · 2020 [cited by applicant]
WO 2020180959A1 · 2020 [cited by applicant]
WO 2020224568A1 · 2020 [cited by applicant]
WO 2020253862A1 · 2020 [cited by applicant]
WO 2021003517A1 · 2021 [cited by applicant]
WO 2021190637A1 · 2021 [cited by applicant]
WO 2002102783A1 · 2022 [cited by applicant]
U.S. Appl. No. 17/608,915, filed Nov. 4, 2021, 2022-0296595, Published. [cited by applicant]
U.S. Appl. No. 18/373,060, filed Sep. 26, 2023, 2024-0066031, Published. [cited by applicant]
U.S. Appl. No. 18/373,067, filed Sep. 26, 2023, 2024-0033264, Published. [cited by applicant]
Yin et al., A highly potent CDK4/6 inhibitor was rationally designed to overcome blood brain barrier in gliobastoma therapy. Eur J Med Chem. Jan. 20, 2018;144:1-28. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2020/088585, dated Jul. 29, 2020, 13 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2019/085494, dated Feb. 12, 2020, 12 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/US2021/030728, dated Jul. 2, 2021, 16 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2021/073515, dated Jun. 7, 2021, 8 pages. [cited by applicant]
You, Medicinal Chemistry, 2nd Edition, China Medical Science and Technology Press, pp. 583-584, Feb. 28, 2011. [cited by applicant]
U.S. Appl. No. 17/608,915, filed Nov. 4, 2021, 2022-0296695, Published. [cited by applicant]
U.S. Appl. No. 18/373,060, filed Sep. 26, 2023, 2024-0066031, Abandoned. [cited by applicant]
U.S. Appl. No. 18/373,067, filed Sep. 26, 2023, 2024-0033264, Abandoned. [cited by applicant]
U.S. Appl. No. 18/785,844, filed Jul. 26, 2024, Pending. [cited by applicant]
Caira, M., “Crystalline Polymorphism of Organic Compounds”, Topics in Current Chemistry, 198:163-208, 1998, 46 pages. [cited by applicant]
International Search Report and Written Opinion for Application No. PCT/CN2024/132256, dated Feb. 5, 2025, 12 pages. [cited by applicant]